Changes after publication

Changes after publication

March 2014: implementation section updated to clarify that paclitaxel is recommended as an option for treating ovarian cancer. Additional minor maintenance update also carried out.

March 2012: minor maintenance

This guidance has been partially updated by 'Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (review)' (NICE technology appraisal guidance 91 [TA91]. Recommendations 1.3, 1.4 and 1.5 on re-challenge therapy and the second-line treatment of advanced ovarian cancer have been replaced. The recommendations for first-line treatment still stand. See TA91 for details of the new recommendations and evidence considered.